Approvals in 2023 Elevate the CRC, HCC, and Pancreatic Cancer Fields, Paving the Way for More to Come
Fruquintinib was approved by the FDA for previously treated metastatic colorectal cancer.
The article reviews FDA approvals in 2023 for gastrointestinal cancers, noting new treatments such as fruquintinib (Fruzaqla) and trifluridine/tipiracil with bevacizumab for metastatic colorectal cancer, and highlights clinical trial data and emerging therapies.
The FDA approval represents a significant advancement in options for patients with metastatic colorectal cancer who have exhausted prior therapies.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Quercetin suppresses the progression of HBV-associated hepatocellular carcinoma by modulating the EGFR signaling pathway
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Surgical treatment of hepatocellular carcinoma: expert consensus statement
- Loco-regional treatment of hepatocellular carcinoma
- Real‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort